Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2018; 78(03): 283-284
DOI: 10.1055/s-0043-124518
GebFra Science
Letter to the Editor
Georg Thieme Verlag KG Stuttgart · New York

mTor Inhibitors for the Treatment of Endometriosis

mTOR-Inhibitoren zur Behandlung von Endometriose
Fabio Barra
1   Academic Unit of Obstetrics and Gynecology, Ospedale Policlinico San Martino, Genoa, Italy
2   Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy
,
Simone Ferrero
1   Academic Unit of Obstetrics and Gynecology, Ospedale Policlinico San Martino, Genoa, Italy
2   Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
21 March 2018 (online)

Also available at
   Permissions and Reprints

We read with great interest the article of Kacan et al. entitled “Everolimus as an mTOR Inhibitor Suppresses Endometriotic Implants: an Experimental Rat Study” [1] published in your journal.

The authors surgically induced endometriosis by the autotransplantation of uterine tissue in the peritoneal cavity of 24 rats. The animals were randomized in three groups, receiving oral everolimus, oral anastrozole, or intravenous saline solution for 14 days. Histological evaluation was done by the endometriosis score (according to Keenan et al. [2]) and immunohistochemical examination was performed by using antibodies against vascular endothelial growth factor (VEGF), CD117 and BAX. The post-treatment analysis of endometriotic implants revealed that anastrozole and everolimus succeeded in significantly decreasing their growth and size with no difference in histological and immunohistochemical results between the two drugs. The authors noted at histology that the number of ovarian follicles was not negatively altered by everolimus, differently from anastrozole that, as evidenced in literature, tends to decrease it [3].

Comment to this article:

Everolimus as an mTOR Inhibitor Suppresses Endometriotic Implants: an Experimental Rat StudyGeburtshilfe Frauenheilkd 2017; 77(01): 66-72
DOI: 10.1055/s-0042-115566

 

  • References

  • 1 Kacan T, Yildiz C, Baloglu Kacan S. et al. Everolimus as an mTOR inhibitor suppresses endometriotic implants: an experimental rat study. Geburtsh Frauenheilk 2017; 77: 66-72
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Keenan JA, Williams-Boyce PK, Massey PJ. et al. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 1999; 72: 135-141
    CrossrefPubMedGoogle Scholar
  • 3 Oral E, Demir B, Inceboz U. Endometriosis and ovarian reserve. Womens Health (Lond) 2015; 11: 671-675
    CrossrefPubMedGoogle Scholar
  • 4 Cinar O, Seval Y, Uz YH. et al. Differential regulation of Akt phosphorylation in endometriosis. Reprod Biomed Online 2009; 19: 864-871
    CrossrefPubMedGoogle Scholar
  • 5 Leconte M, Nicco C, Ngo C. et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol 2011; 179: 880-889
    CrossrefPubMedGoogle Scholar
  • 6 Wesolowski R, Abdel-Rasoul M, Lustberg M. et al. Treatment-related mortality with everolimus in cancer patients. Oncologist 2014; 19: 661-668
    CrossrefPubMedGoogle Scholar
  • 7 Gajate P, Alonso-Gordoa T, Martinez-Saez O. et al. Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms. Clin Transl Oncol 2017; DOI: 10.1007/s12094-017-1758-3.
    CrossrefPubMedGoogle Scholar
  • 8 Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 2013; 12: 177-186
    CrossrefPubMedGoogle Scholar